Ensuring equity in the era of HLA-restricted cancer therapeutics
In January 2022, the US Food and Drug Administration granted regulatory approval to tebentafusp, a bispecific T cell receptor protein that targets melanoma antigen gp100 in the context of the human leucocyte antigen (HLA) A*0201 allele. This approval generated significant excitement, given the relat...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2022-11-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/10/11/e005600.full |